Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOGETHER-PsO: Ixekizumab and Tirzepatide in Plaque Psoriasis and Obesity
NCT06588283Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Primary completion
- Jan 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tirzepatide in plaque psoriasis and obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction at 36 weeks. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
plaque psoriasisobesity
Beyond the preview
Go deeper on NCT06588283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588283.